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Abstract
Objectives: To estimate the cost savings and health benefits in the UK NHS that could be achieved if human milk
usage in the NICU was increased.
Methods: A systematic review established the disease areas with the strong sources of evidence of the short,
medium and long-term benefits of human milk for preterm infants as opposed to the use of formula milk. The
analysis assessed the economic impact of reducing rates of necrotising enterocolitis, sepsis, sudden infant death
syndrome, leukaemia, otitis media, obesity and neurodevelopmental impairment.
Results: Based on the number of preterm babies born in 2013, if 100% of premature infants being fed mother’s
milk could be achieved in the NICU, the total lifetime cost savings to the NHS due to improved health outcomes is
estimated to be £46.7 million (£30.1 million in the first year) with a total lifetime QALY gain of 10,594, There would
be 238 fewer deaths due to neonatal infections and SIDS, resulting in a reduction of approximately £153.4 million
in lifetime productivity. Sensitivity analyses indicated that results were robust to a wide range of inputs.
Conclusions: This analysis established that increasing the use of human milk in NICUs in the UK would lead to cost
savings to the NHS. More research is needed on the medium and long term health and economic outcomes
associated with breastfeeding preterm infants, and the differences between mother’s own and donor breast milk.
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Background
The benefits of human milk for both preterm and term
infants are well established in the medical literature,
with evidence demonstrating that human milk can aid
development and reduce risks of certain infections [1].
The World Health Organization (WHO) recommends
exclusive breastfeeding for at least the first 6 months of
life to provide adequate nutrition for infant development
[2, 3]. Yet, the most recent Infant Feeding Survey shows
that very few mothers in the UK are following these rec-
ommendations: in 2010 only 69% of mothers exclusively
breastfed at birth, with rates falling to 1% at 6 months
[4]. Barriers to breastfeeding in the UK include personal
and society biases towards breastfeeding, issues with
feeding in public and employment practices [5].
Mothers with preterm infants face further barriers to
breastfeeding. For infants that are born preterm
(<37 weeks of pregnancy), providing human milk to the
infant and sustaining lactation up to and beyond hospital
discharge may be challenging [6]. In the UK, the rate of
exclusive breastfeeding at discharge for preterm infants
has been found to be as low as 29% and for exclusive of
mixed breastfeeding as low as 35% [7]. In these circum-
stances, feeding with donor breastmilk from other lactat-
ing mothers has been shown to have benefits over
feeding formula milk, such as a lower risk of necrotising
enterocolitis (NEC) in the infant due to the presence of
active enzymes and anti-infective properties in the
breastmilk [8].
In addition to the health benefits, the economic case
for breastfeeding term infants has also been addressed.
The 2012 UNICEF report on diseases and developmental
deficits associated with low breastfeeding rates in the
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UK estimated that a moderate increase in breastfeeding
could lead to fewer hospital admissions and GP consul-
tations from conditions such as asthma, leukemia,
coeliac disease, cardiovascular disease and sepsis [9].
Supporting mothers to breastfeed exclusively for the first
4 months could save the NHS over £11 million per year
by reducing the incidence and treatment costs for acute
infections such as gastrointestinal and lower respiratory
tract infections, and acute otitis media in infants [10].
This is by no means an issue specific to the UK, with a
recent study estimating that the international impact of
not breastfeeding is associated with economic losses of
about $302 billion annually, or 0 · 49% of world gross
national income [11].
The economic value of increasing human milk feeding
for preterm infants is therefore potentially high. For ex-
ample, recent research indicates that increasing the rate
of breastfeeding at discharge in UK neonatal units could
save the NHS £6.12 million per year from reduced costs
of treating NEC in preterm infants [10]. However, the
total economic value of human milk feeding covering all
the short and long term benefits (such as the reduction
of chronic conditions such as coronary heart disease
(CHD) and obesity [12], and neurodevelopmental im-
pairment (NDI) resulting from acute infections [13]) has
not been estimated.
The purpose of the research was explicitly not to dem-
onstrate or speculate on the underlying biological rea-
sons as to why human milk confers benefit to preterm
infants or to speculate on how rates could be increased.
Rather, the aim of the research was to highlight the
potential economic benefit that could result from the in-
crease in human milk consumption on preterm infants
based upon previously published odds ratios on specific
outcomes depending on whether infants were fed for-
mula or human milk. Specifically, the research aimed to
show the potential health benefits and cost savings to
the NHS in England and Wales as an exemplar of sav-
ings in a developed economy.
Methods
Literature review
In constructing the economic model, the first step was to
conduct a literature search to identify literature reviews
that provided evidence of the benefits of human milk and
breastfeeding for preterm infants as opposed to the use of
formula milk. The question was defined using the PICOS
framework (details given in Online Resource 1) focusing
on preterm infants and feeding human milk compared
with infant formula. Reported short, medium and long-
term benefits or outcomes from human milk and/or
breastfeeding were eligible for inclusion. There are a large
number of existing evidence syntheses which have sum-
marised, analysed and appraised the primary research
evidence in this field. Therefore we chose to include litera-
ture reviews to inform the model, with systematic reviews
taking precedence over pragmatic reviews.
A focused search of the following resources was
undertaken: Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of Effects
(DARE), Health Technology Assessment Database (HTA
Database) all via the Cochrane Library, and MEDLINE
and MEDLINE In-Process via Ovid SP. The searches
were limited to material published from 2000 to current
in order to prioritise the most recent evidence. The
search strategy used to search Ovid MEDLINE is pre-
sented in Online Resource 1.
To identify any relevant reviews that might have been
missed by the database searches, particularly reviews
that have not been published as a journal article or book
chapter, webpages of relevant organisations were
browsed and/or searched, including the World Health
Organisation, The Partnership for Maternal, Newborn
and Child Health, UNICEF, Save the Children, USAID,
Women and Health Alliance International, World
Alliance for Breastfeeding Action, and CARE International.
Economic modelling
The aim of the economic modelling was to estimate the
cost savings and health benefits in the NHS in England
and Wales that could be achieved if human milk usage
and breastfeeding rates in preterm infants in neonatal
intensive care units (NICUs) were increased. England
and Wales were chosen rather than the whole of the UK
due to data availability in those nations and that the
population in England and Wales accounts for approxi-
mately 90% of the UK population.
In order to estimate the extent of cost savings and
health benefits associated with increased human milk
usage and breastfeeding rates in the NICU, two scenar-
ios were defined: the base case scenario which reflects
the current level of human milk usage and breastfeeding
in preterm infants in England and Wales of 35% [7], and
a hypothetical scenario which reflects 100% human milk
feeding of preterm infants at least until the age of
6 months. It should be recognized that for preterm in-
fants in the neonatal intensive care unit mothers’ own
milk often needs to be fortified and in these instances it
is still classed as exclusive human milk feeding and
breastfeeding if the infant’s intake is not further supple-
mented with formula.
The analysis assessed outcomes in infants in the
NICU. Infants who were exclusively human milk fed
at discharge were compared with infants who were
never fed human milk (fed with formula milk). After
discharge from NICU, the analysis compared out-
comes in infants who received some human milk in
the NICU (including those who were exclusively and
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non-exclusively breastfed) with those who received no
human milk (formula fed) infants.
Outcomes were assessed at the population level. The
number of preterm infants born in 2013 in England and
Wales was 51,703, which was obtained from a dataset
published by the Office for National Statistics (ONS) [14].
Outcomes included in the model were identified in the
literature review described above, and from reviewing pre-
vious economic evaluations of the impact of breastfeeding
[9, 10]. For each of the disease outcomes included in the
model, an odds ratio was used to model the benefit of
breastfeeding to represent the degree to which the rate of
the disease outcome would be decreased. To note, the
paper is explicitly not about what is determining the odds
ratio and why breast milk is beneficial to infants; it is a
health economics analysis treating human milk as an
intervention using the existing evidence of its effective-
ness. The outcomes include: sepsis; necrotising entero-
colitis (NEC); sudden infant death syndrome (SIDS);
acute otitis media (AOM); childhood leukaemia; child-
hood obesity and the associated impact on developing
Type II Diabetes and coronary heart disease (CHD)
later in life; and neurodevelopment impairment (NDI)
and disability.
The primary economic analysis took the perspective of
the NHS. Costs that fall on individuals, households or
any other sectors were excluded. Quality of life was mea-
sured in quality-adjusted life years [15]. The costs to the
society were included in a secondary analysis, whereby
the impact on lifetime economic productivity due to
averted deaths was assessed.
Each disease outcome was modelled over different
time horizons. For NEC and sepsis, the length of stay in
neonatal units was considered as the time horizon for
costing. For acute conditions that occur in childhood
(AOM and SIDS), it was the first year of life. Disability
and the chronic conditions that were associated with
childhood obesity (Type II Diabetes and CHD) were
modelled over the infants’ lifetime. Where the costing
time horizon is longer than a year, a rate of 3.5% per
year was used to discount the future stream of treatment
costs in baseline estimates [16].
The model used the following steps to estimate the
cost savings and health benefits associated with mothers’
own milk versus formula is outlined in Fig. 1.
A summary of all inputs used in the model is provided
in Table 1.
Results
Results of the literature review
The search strategies retrieved 1,612 records, after dedu-
plication 1,418 records remained, with the majority of
records (1,271) sourced from MEDLINE. After an initial
screening, 845 records were reviewed for further
assessment.
As this is a pragmatic review with the purpose of iden-
tifying evidence for benefits of human milk and/or
breastfeeding, only the most recent reviews reporting
either a specific outcome or at one of our three time
points of interest were included. Other reviews were
only considered for inclusion if they provided either in-
formation from different individual studies or on differ-
ent outcomes at the same time point. Studies on term
infants were only considered where there was an ab-
sence of evidence at a given time point or on a specific
outcome at a given time point for preterm infants.
Outcomes and evidence availability
The majority of evidence on outcomes is for term in-
fants, with no reviews providing evidence of long-term
The expected number of children experiencing each health outcome was estimated in 
a population receiving human milk at discharge and in a population receiving formula. 
This was estimated using the population incidence rate to determine the number of 
events in the general population, and an odds ratio of the event to determine the 
number of events in an exclusively human-milk fed population and in a formula-fed 
population.
The estimated costs and QALYs were estimated for each population. The cost of 
treatment and the utility estimate for the duration of the event were applied to the 
number of children estimated to have experienced the event.
The costs and QALYs in each population were combined to estimate total impact of the 
disease in each population.
Total treatment costs and QALYs under each scenario were compared to ascertain the 
extent to which increasing breastfeeding rates would reduce health service costs and 
improve quality of life.
Fig. 1 Model diagram. Presents the calculation steps in the model. Abbreviations. QALY: quality-adjusted life year
Mahon et al. Health Economics Review  (2016) 6:54 Page 3 of 8
Table 1 Modelling inputs
Outcome Baseline incidence Odds ratio Treatment cost Mortality Quality of life
Medical NEC 3.5% for birth weight 500–999 g
2.1% for birth weight 1000–1749 g
0.5% for birth weight 1750–2500 g [21]
MM vs MM + formula:
0.412 [22]
Formula vs MM and
formula: 3.006 [23]
27.2 days stay in NICU [24]
Cost per day of £630.08 based
on weighted average of neonatal
critical care codes [25]
Total cost of £1,739
N/A N/A
Surgical NEC 3.3% for birth weight 500–999 g
0.6% for birth weight 1000–1749 g
0.1% for birth weight 1750–2500 g [21]
As for medical NEC £1,739 (non-elective inpatient:
major neonatal diagnosis) [25]
Plus incurs cost of medical
NEC treatment.
Total cost of £18,877.
N/A N/A
Sepsis 27.2% for birth weight 500–999 g
8.2% for birth weight 1000–1749 g
4.7% for birth weight 1750–2500 g [26]
MM vs MM + formula:
0.707 [22]
Formula vs MM and
formula: 0.803 [27]
5.9 days stay in NICU [24]
Cost per day of £630.08 based
on weighted average of neonatal
critical care codes [25]
Total cost of £17,138.
N/A N/A
Mortality in NICU 20.5% for birth weight 500–999 g [28]
8.0% for birth weight 1000–1749 g [29]
5.0% for birth weight 1750–2500 g [30]
If medical NEC: 2.055 [28]
If surgical NEC: 3.124 [28]
If sepsis. 3.219 [29]
N/A N/A Lost (discounted) QALYs per premature
death of on average 23.6. Based on
mean life expectancy and age-related
quality of life [31, 32]
SIDS 0.07% (per live birth) [33] 0.40 (any breastfeeding versus
formula) [34]
£72 (VB11Z: Emergency Mediine,
No Investigation with No
Significant Treatment) [25]
N/A Lost (discounted) QALYs per premature
death of on average 23.6. Based on
mean life expectancy and age-related
quality of life [31, 32]
AOM 0.14% (for infants under the age of 1) [10] 0.40 (any breastfeeding versus
formula) [35]
£46 - visit to a general practitioner [36] N/A N/A
Leukaemia 0.04% (cumulative incidence up to
age 15) [37]
0.91 (any breastfeeding versus
formula) [38]
£114,456 per case of leukaemia
(includes all treatment-related costs) [39]
92% survival rate [40] 0.66 on treatment [41]
Obesity 9.5% (proportion children aged 4 to 5
defined as obese) [42]
Probability of an obese child being an
obese adult: 65% [43]
0.79 (any breastfeeding versus
formula) [12]
N/A (see diabetes and CHD) N/A (see diabetes and CHD) N/A (see diabetes and CHD)
Type 2 diabetes 9.61% (prevalence in obese adults) [44] N/A £787 per year [45] Age at diagnosis: 55
Life expectancy: 75 [46]
0.866 [45]
CHD 6.04% (prevalence in obese adults) [44] N/A £1,974 per year [45] Age at diagnosis: 65
Life expectancy: 75 (assumption)
0.867 [45]
NDI 49% for birth weight 500–999 g
41% for birth weight 1000–1749 g
34% for birth weight 1750–2500 g [47]
Mild NDI: 65%
Moderate NDI: 22%
Severe NDI: 14% [47]
Given sepsis: 2.282 [29]
Given medical NEC: 1.187 [28]
Given surgical NEC: 1.985 [28]











Presents a summary of parameter values used in the economic analysis. Abbreviations: NEC necrotizing enterocolitis, MM mother’s own milk, NICU neonatal intensive care unit, QALY quality-adjusted life year, SIDS














outcomes of either expressed human milk or breastfeed-
ing to preterm infants. The only medium-term outcome
for preterm infants is NEC and it is not clear in the re-
view at what time point this was relevant. In addition,
this was a review of donor human milk rather than the
mother’s own milk [17]. The short-term outcomes are
from a review of low birth weight rather than preterm
infants [13].
The evidence is mixed for long-term outcomes. For
some outcomes, such as obesity and IQ, some reviews
conclude there is no effect of human milk or breastfeed-
ing, and others conclude that there is.
More details on the availability of evidence on out-
comes for preterm and term infants and included re-
views can be found in Online Resource 1.
Results of the economic model
Outcomes in the NICU
The estimated impact of providing human milk on out-
comes in the NICU is presented in Fig. 2.
The total cost savings to the NHS due to these events
is therefore estimated to be £30.1 million for the year.
The average saving per infant would be £583.
Due to the number of deaths averted, the total QALY
gain in the NICU attributed to increased levels of breast-
feeding is 4,568. This is an average QALY gain per infant
of 0.088. The National Institute for Health and Care Ex-
cellence (NICE) recommends a willingness to pay per
QALY of £20,000 [16] Given this value, the value of the
QALY gains for the cohort is equivalent to £91.4 million,
and £1,767 per infant. When combined with the hospital
cost savings due to fewer episodes of infection, the net
value is £121.5 million.
Outcomes after NICU discharge
The long-term benefits associated with increased levels
of breastfeeding are presented in Table 2. Disability
arising from NDI was associated with the greatest im-
pact on cost savings and QALY gain, since it is the con-
dition that will have the longest impact over the infant’s
lifetime. Reducing the rate of SIDS is also associated
with a significant QALY gain. The QALY gain for leukae-
mia, diabetes and CHD are relatively small. This is due
to diabetes and CHD occurring in the future of the in-
fant, where outcomes will be most heavily discounted.
The analysis only includes the case of these two condi-
tions that can be attributed to obesity in childhood-
other members of the cohort may develop diabetes or
CHD but this will be due to risk factors other than
childhood obesity. Leukaemia is a relatively rare condi-
tion, so the overall impact of reducing levels of this
condition will be minimal. It is also now associated with
a more optimistic outlook, with a high survival rate (and
therefore a smaller QALY loss per case).
After discharge from NICU, total cost savings of ap-
proximately £16.6 million and a total of 6,026 additional
QALYs for the cohort (£321 savings and 0.12 gained
QALYs per infant) over a lifetime were estimated to be
gained due to increased levels of human milk usage and
exclusive breastfeeding at discharge from the NICU.
Given a willingness to pay per QALY of £20,000, the
value of these QALY gains for the cohort is equivalent to
£120.5 million, and when combined with the cost sav-
ings, the net value is £137.1 million.
Impact to society
The primary outcomes of this analysis are those that are
relevant to the NHS or the hospital (in terms of cost
savings), and to the patient (for improvement in quality
of life and reduction in risk of disease and illness). There
are further benefits that can be observed from a societal
perspective regarding productivity gains due to averting
the loss of earnings due to early death.
Fig. 2 Outcomes in the NICU. Presents the expected number of events experienced by infants while in a NICU. The red bar represents outcomes
for infants fed with mother’s own milk. The blue bar represents outcomes for infants fed with formula. Results are based on a population of
51,703 preterm infants. Abbreviations. NICU: neonatal intensive care unit. NEC: necrotizing enterocolitis
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The analysis estimates that with the introduction of
exclusive breastfeeding, there would be 190 fewer deaths
due to neonatal infections and 48 fewer deaths due to
SIDS. The resulting reduction in loss of lifetime eco-
nomic productivity can be estimated using the estimated
lifetime earnings [18]. The average lifetime productivity
has been estimated at approximately £645,500 (ranging
from £540,500 for low, up to £750,500 for highly edu-
cated workers). Based on 238 lives saved, a reduction of
approximately £153.4 million in lifetime productivity is
observed in the analysis.
Sensitivity analysis
Deterministic sensitivity analysis (DSA) was performed
to examine the effect of changes in key model parame-
ters, where each parameter was varied according to the
measure of dispersion (95% confidence intervals). Re-
sults of the DSA are presented in the format of the im-
pact on the total cost savings for the cohort.
Figure 3 presents the results of the DSA. The tornado
diagram indicates that results were robust to a wide
range of inputs, with the odds ratio for developing sepsis
and for developing NEC the variables with the largest
effect on the results.
Discussion
Main findings
The economic model estimated that increased levels of
human milk usage and breastfeeding in the NICU could
save the NHS £30.1 million (£583 per infant) over the
course of a year from fewer episodes of NEC and sepsis
and 190 fewer deaths. The total discounted lifetime
savings to the NHS for premature infants born each year
from increased levels of human milk consumption in the
NICU would be £46.7 million.. The average lifetime
saving per infant is estimated to be approximately £904
with an average QALY gain of 0.2. This compares to a
Table 2 Long-term benefits of increased levels of breastfeeding
Condition Cases averted Total cost savings Total QALY gain
SIDS 48.03 £3,458 1,133.39
AOM 97.38 £4,480 -
Leukaemia 2.02 £231,148 3.06
NDI 259.17 £16,178,047 1,358.38
Diabetes 74.66 £121,506 11.27
CHD 46.86 £75,219 0.75
Presents the long-term benefits to the population of providing mother’s own
milk to preterm infants. Results are based on a population of 51,703 preterm
infants. Abbreviations: QALY quality-adjusted life year, SIDS sudden infant
death syndrome, AOM acute otitis media, NDI neurodevelopmental impairment,
CHD coronary heart disease
Fig. 3 Tornado diagram for breast milk versus formula. Presents the impact of key parameters in the analysis on the potential total cost savings
for the cohort of the use of mother’s milk versus formula. The blue bars correspond to the high value of the parameter; the red bars correspond
to the low value of the parameter. Results are based on a population of 51,703 preterm infants. Abbreviations. OR: odds ratio. MM: mother’s milk.
NDI: neurodevelopmental impairment. NEC: necrotizing enterocolitis. ALL: acute lymphoblastic leukaemia. AOM: acute otitis media. SIDS: sudden
infant death syndrome
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potential cost saving from a previous review of interven-
tions to increase breastfeeding rates in neonatal units of
between £66 and £586 per infant which whilst poten-
tially lower than found in this study represents all low
weight babies and not just those that were preterm [13].
Whilst the proximity of the numbers between the previ-
ous review and this study are supportive of the findings
in both, the studies are of slightly different populations
and this study looked at lifetime savings and QALY gains
rather than the previous review that just estimated
short-term savings to the NICU. In addition the previous
review looked at the intervention being an activity to in-
crease breastfeeding whilst this study looked at the max-
imum benefit that could be achieved from human milk
as the intervention itself.
The analysis estimates that with the introduction of
exclusive breastfeeding, there would be 190 fewer deaths
due to neonatal infections and 48 fewer deaths due to
SIDS. This is associated with an economic impact of
£153.4 million in lifetime productivity.
Longer-term health benefits of human milk usage and
breastfeeding in the NICU after discharge may include
lower incidence of SIDS within the first year of life, otitis
media, leukaemia, diabetes, CHD and disability arising from
NDI. Disability was associated with the greatest impact on
cost savings and QALY gain, since it is the condition that
has the longest impact over the infant’s future life. The
long-term outcome results were based on the calculated
population of preterm infants who were able to receive
some level of (as opposed to exclusive) human milk. How-
ever, it must be stated that these numbers are estimates as
most evidence on outcomes identified was for term infants
with no reviews providing evidence of long-term outcomes
of either human milk or breastfeeding to preterm infants.
Although this approach is most likely to provide conserva-
tive outcomes given that preterm infants are associated
with greater rates of neurological impairment [19].
The literature review performed as a part of this research
highlighted the need for more high-quality studies on out-
comes of human milk and breastfeeding of preterm infants.
In addition, more research is needed on the medium and
long-term outcomes of breastfeeding infants. As is the case
with all economic models based on the limited data that is
currently available, the results should be interpreted with
caution. Although, the outcomes of this study agree in
principle with previous economic impact analyses [10] on
increasing breast feeding rates in all babies, suggesting that
the beneficial effects of human milk on the infant over the
short- and long-term are real. Sensitivity analysis per-
formed as part of this study also showed that the savings
and patient benefits exist across the range of potential
values that exist for breast milk benefit identified in the
literature. Thus the cautionary not on whether the benefits
and economic impact actually exists, but rather in relation
to the strength of those benefits and the magnitude of the
positive economic impact.
The results presented in this research illustrate a best-
case scenario for human milk feeding for preterm infants.
In reality, human milk usage and breastfeeding in the
NICU may be difficult due to the infant’s condition, or
mother’s own milk availability. However, increased feeding
of human milk has many potential health and economic
benefits to both term and preterm infants, so feeding pre-
term infants mother’s own breastmilk, or donor milk
should be encouraged whenever possible [20]. The results
presented may underestimate the true benefits of human
milk usage in the long term; the results post-discharge are
based on infants receiving mixed feeding (formula and
human milk) up to the age of 6 months, representing a
conservative scenario. There is an increase in benefit of
providing human milk for longer, and a further benefit
for a longer duration of exclusive breastfeeding [1]. In
addition, there are also established benefits to the
mother in terms of a reduced risk of breast cancer, but
this has not been addressed in this analysis.
Conclusion
The health benefits of providing human milk to preterm
infants have long been established. This new analysis
established that increasing human milk usage and breast-
feeding rates in NICUs in England and Wales could also
lead to cost savings to the NHS, relating both to the
short-term reduction in infections in the NICU, and to
the impact of reducing long-term associated conditions. It
is important to note that no attempt was made to identify
potential methods to increase human milk feeding in neo-
natal units for preterm infants, but the cost saving to the
NHS per infant suggests that significant resource could be
dedicated on interventions to raise human milk feeding
rates and the intervention still be cost saving overall. The
economic benefits are established and real and could po-
tentially be realized with little effort but just a change in
approach in NICUs and appropriate support to parents.
More research is needed on the health and economic out-
comes associated with breastfeeding, and the differences
between mother’s own and donor breast milk.
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